Tecentriq (Atezolizumab) Market Report 2026

Tecentriq (Atezolizumab) Market Overview

• The Tecentriq (Atezolizumab) market growth in the historic period has been driven by limitations of chemotherapy, breakthrough immunotherapy approvals • Market expansion is supported by growth in oncology clinical trials, expansion of biomarker-based treatment • Growth Driver: Rising Cancer Prevalence And Its Impact On The Growth Of The Tecentriq (Atezolizumab) Market • Market Trend: Innovation And Approvals Driving Growth In The Tecentriq (Atezolizumab) Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tecentriq (Atezolizumab) Market?

Tecentriq (atezolizumab) is a monoclonal antibody-based immunotherapy, which belongs to a class of cancer treatments known as immune checkpoint inhibitors and specifically targets the protein programmed death ligand 1 (PD-L1). It blocks the interaction between PD-L1 (found on tumor cells and immune cells) and PD-1 or B7.1 receptors (on T-cells). This inhibition reactivates the immune system, enabling T-cells to detect and destroy cancer cells. The main types of tecentriq (atezolizumab) are pd-l1 inhibitors, pd-1 inhibitors, ctla-4 inhibitors, immunomodulators, and others. Tecentriq PD-L1 Inhibitor is a monoclonal antibody that blocks PD-L1, a protein that inhibits the immune response to cancer cells. It is used for lung cancer, bladder cancer, melanoma, hodgkin's lymphoma, head and neck cancer, and others and is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. It is used by different types of end users, including hospitals, homecare, specialty clinics, and others.

What Is The Tecentriq (Atezolizumab) Market Growth Forecast?

The tecentriq (atezolizumab) market size is expected to see rapid growth in the next few years. It will grow to $7.65 million in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growth in oncology clinical trials, expansion of biomarker-based treatment, increased cancer screening rates, rising healthcare investment in oncology, improved survival outcomes. Major trends in the forecast period include rising adoption of immune checkpoint inhibitors, expansion of indications across multiple cancers, increased use of combination immunotherapy, growth in precision oncology approaches, shift toward personalized cancer treatment.

What Is The Driver Of The Tecentriq (Atezolizumab) Market?

The rising prevalence of cancer is expected to drive the growth of the tecentriq (atezolizumab) market going forward. The increasing prevalence of cancer can be attributed to factors such as an aging population, better detection methods, lifestyle changes, environmental exposures, and improved survival rates, all of which contribute to more people being diagnosed and living with cancer. Tecentriq (atezolizumab) is required for cancer management because it harnesses the immune system to fight cancer by blocking PD-L1, a protein that allows tumors to evade immune detection, thereby enabling the immune system's T-cells to recognize and destroy cancer cells more effectively. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. Therefore, the rising prevalence of cancer is driving the growth of the Tecentriq (Atezolizumab) industry.

Key Players In The Global Tecentriq (Atezolizumab) Market

Major companies operating in the tecentriq (atezolizumab) market are Roche Holding AG, Chugai Pharmaceutical Co. Ltd

Global Tecentriq (Atezolizumab) Market Trends and Insights

The key trend in the tecentriq (atezolizumab) market is focusing on developing innovative products, such as intravenous formulations of atezolizumab, to ensure precise dosing, rapid systemic absorption, and consistent therapeutic levels. The intravenous formulation of atezolizumab is a liquid preparation administered directly into the bloodstream via infusion, designed to deliver the monoclonal antibody efficiently for systemic treatment of cancer. For instance, in September 2024, Genetech Inc., a US-based biotechnology company, received the U.S. Food and Drug Administration approval for atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Tecentriq, the first subcutaneous anti-PD-L1 therapy approved in the U.S., offers a unique advantage with its faster administration time of approximately 7 minutes compared to the 30-60 minutes required for intravenous infusion, while maintaining comparable efficacy in drug exposure and overall response rates, as demonstrated in the IMscin001 trial. It is indicated for multiple adult cancers, including NSCLC, SCLC, melanoma, hepatocellular carcinoma, and alveolar soft part sarcoma.

What Are Latest Mergers And Acquisitions In The Tecentriq (Atezolizumab) Market?

In October 2024, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition company, acquired the Vacaville large-scale biologics manufacturing facility of Roche for a deal of $1.2 billion. The acquisition establishes a strong West Coast commercial manufacturing presence near San Francisco’s biotech hub, complementing Lonza’s existing East Coast site in Portsmouth, New Hampshire, and its global network in Europe and Asia Pacific. This expansion greatly strengthens Lonza's ability to manufacture late-stage clinical and commercial products, as well as support the production of new molecules approaching commercialization. Roche Holding AG is a Switzerland-based manufacturer of pharmaceuticals and biologics such as tecentriq (atezolizumab).

What Defines the Tecentriq (Atezolizumab) Market?

The tecentriq (atezolizumab) market consists of sales of biosimilars, immuno-oncology pipeline drugs, supportive oncology medications and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tecentriq (Atezolizumab) Market Report 2026?

The tecentriq (atezolizumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tecentriq (atezolizumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.